Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06390930 · ClinicalTrials.gov registry record · NA
Effects of Acute Intermittent Hypoxia on Neuroplasticity in MS
A NA study of Multiple Sclerosis and Multiple Sclerosis (Relapsing Remitting), sponsored by Shirley Ryan AbilityLab.
- Recruiting
- Registry status
- NA
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT06390930: Recruiting NA study of Multiple Sclerosis and Multiple Sclerosis (Relapsing Remitting), sponsored by Shirley Ryan AbilityLab.
NCT06390930 is a NA study of Multiple Sclerosis and Multiple Sclerosis (Relapsing Remitting) that is actively recruiting participants, run by Shirley Ryan AbilityLab. The registered enrollment target is 22 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06390930, a NA study of Multiple Sclerosis and Multiple Sclerosis (Relapsing Remitting), is actively recruiting participants, sponsored by Shirley Ryan AbilityLab.
- RECRUITING
- Registry status
- NA
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
This study seeks to explore changes in the neural pathways and arm function following a breathing intervention in the multiple sclerosis (MS) population. The breathing intervention, known as Acute Intermittent Hypoxia (AIH), involves breathing brief bouts of low levels of oxygen. Research has found AIH to be a safe and effective intervention resulting in increased ankle strength in people with MS. Here, the study examines arm and hand function before and after AIH. In order to better understand the brain and spinal cord response to AIH, the investigators will measure muscle response, and signals sent from the brain to the arm muscles before and after AIH.
Primary Outcome
The MEPs will be elicited by Transcranial Magnetic Stimulation (TMS), a procedure that uses magnetic fields to stimulate nerve cells in the brain.
Conditions Studied
Interventions
- OTHER Acute Intermittent Hypoxia
- OTHER Sham Acute Intermittent Hypoxia
Study Locations (1)
Illinois
- Shirley Ryan AbilityLab - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2025-02-01 |
| Est. Completion | 2027-07 |
| Phase | NA |
What NCT06390930 shows while recruiting
NCT06390930 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (96% lower).
The record links to 3 conditions, with Multiple Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which Acute Intermittent Hypoxia is the first listed.
NCT06390930 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT06390930 about?
NCT06390930 is a clinical study titled "Effects of Acute Intermittent Hypoxia on Neuroplasticity in MS". This study seeks to explore changes in the neural pathways and arm function following a breathing intervention in the multiple sclerosis (MS) population. The breathing intervention, known as Acute Intermittent Hypoxia (AIH), involves breathing brief bouts of low levels of oxygen. Research has found ...
What is the current status of trial NCT06390930?
This trial is currently recruiting. It is a NA study. The enrollment target is 22 participants. The study started on 2025-02-01. Estimated completion is 2027-07.
What conditions does trial NCT06390930 study?
This clinical trial studies the following conditions: Multiple Sclerosis, Multiple Sclerosis (Relapsing Remitting), Multiple Sclerosis, Secondary Progressive.
What interventions are being tested in trial NCT06390930?
The interventions under investigation include: Acute Intermittent Hypoxia (OTHER), Sham Acute Intermittent Hypoxia (OTHER).
Who is sponsoring clinical trial NCT06390930?
This trial is sponsored by Shirley Ryan AbilityLab, which has 138 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06390930 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06390930's enrollment target sits among peer trials
22 256th of 315 higher than 58 of 315 other Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Prepare the Mind: Can Coaching in Goal-directed Behaviour Increase the Success of Cognitive Rehabilitation in People With MS?
RECRUITING · NA
-
Incremental Vestibulo-ocular Reflex Adaptation as a Novel Treatment for Dizziness in People With Multiple Sclerosis
RECRUITING · NA
-
Intermittent Hypoxia in Persons With Multiple Sclerosis
RECRUITING · NA
-
Investigating the Effects of Wearable Robotic Exoskeleton for Improving Mobility and Cognition in Persons With MS
RECRUITING · NA
-
Central Vein Sign in Multiple Sclerosis Extension Study
RECRUITING · NA
-
Effects of Torso Weighting on Muscle Activation During Balance Tests in Individuals With and Without Multiple Sclerosis
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI